Member Info for PhilBanks

Great update and delighted that the company has stuck to its published timeline. Thanks for the research paper and patent links, I shall review over coffee.

For info, Mereo BioPharma up over 50% from that 27th Jan RNS.

Thanks Donacropolis, I hadn't previously picked up that reference to the clause relating to rene, so it's useful you have pointed this out. The article linked below summarises it as follows:

'In addition, the Company and the Buyer have agreed to a potential adjustment to the acquisition price in the event of significant changes in value of the listed portfolio companies Mereo BioPharma and ReNeuron on an aggregated basis by the date of completion of the Transaction.'

https://newsnreleases.com/2021/01/27/schroder-to-sell-49-0-million-worth-of-assets-to-rosetta-capital/

Link below to a nugget of information that may be of interest; it's a circular from Fosun Pharma dated December 2020, outlining a share issue to fund the development of various drug programmes:

https://www.fosunpharma.com/uploads/2020120752938.pdf

If you open the link and press 'ctrl' and 'f', then search for 'rene', you will find some references to the CTX and hRPC trials, along with associated figures. Appendix 1, items 10 and 11 are of interest.

Item 10 relates to the CTX programme ( Phase IIb clinical trials for disability after ischemic stroke in mainland China and Taiwan region), with 113m RMB (Chinese Yuan) outlined for the purpose of; "Introduce stem cell therapy (CTX) ReNeuron Group Plc for the exclusive clinical R&D and commercialization license of disability after ischemic stroke, and pay the subsequent expenses such as R&D milestone payments".

From that figure, it appears that 26m RMB (approx. £2.9m) is for R&D milestone payments to Rene.

Item 11 relates to the hRPC programme (Phase IIb clinical trials for retinitis pigmentosa in mainland China and Taiwan region) with 110m RMB (Chinese Yuan) outlined for the purpose of; "Introduce stem cell therapy (hRPC) from ReNeuron Group Plc for the exclusive clinical R&D and commercialization license of retinitis pigmentosa, and pay the subsequent expenses such as R&D milestone payments."

From that figure, it appears that 53m RMB (approx. £5.9m) is for R&D milestone payments to Rene.

I think my interpretation of the figures is correct, but would be useful to get some other opinions. Clearly this isn't necessarily money in the bank for Rene (as we can presumably expect a large chunk of that money will relate to successful completion of those trials), however it is good to see everything is continuing to progress with regards to the Fosun arrangement, as frankly I don't think we've really had much further info on this since the deal was signed a couple of years ago.

Also worth noting that for hRPC it says 'Phase IIb' trial, whereas obviously it was (and still is for the in-house work) a Phase IIa trial when the deal was signed, so perhaps and indication of some further progress being made there.

FYI, this was updated yesterday by the looks of things.

https://clinicaltrials.gov/ct2/show/study/NCT02464436

Oregon and Barcelona have been added by the looks of it (based on comparison with Clive's post on Thursday). Arizona now saying active and not recruiting.

Locations
United States, Arizona
Retinal Research Institute Active, not recruiting
Phoenix, Arizona, United States, 85053
United States, Massachusetts
Massachusetts Eye and Ear Infirmary Recruiting
Boston, Massachusetts, United States, 02114
Contact: Jason Comander, MD 617-573-6060 ophthalmologyclinicalresearch@meei.harvard.edu
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Mark Pennesi, MD
Contact: Sreesha Sreedhar, M.B.,B.S, M.S 503-494-9771 sreedhas@ohsu.edu
Spain
Institut de la Màcula Not yet recruiting
Barcelona, Spain
Contact: Jordi Monés, MD +34 935 95 01 55
United Kingdom
Oxford Eye Hospital Not yet recruiting
Oxford, United Kingdom, OX3 9DU
Contact: Robert MacLaren, Professor

Also, just noticed that you can do a side-by-side comparison of how the study has been changed since it was first published (hopefully this link works):
https://clinicaltrials.gov/ct2/history/NCT02464436?A=1&B=10&C=Side-by-Side#StudyPageTop

That previous post was meant to say CTX and not CBX obviously, but you get the gist.

I'm still trying to piece together what this is telling us, as for me it really has come out of the blue. However, what is clear is that since Obotritia have become significant investors and Mark Evans has been put on the board, the company has sidelined the CBX trial for licencing, the company has engaged with shareholders significantly more (3 investor presentations in the last 2 weeks), a new joint broker has been appointed, a PR/IR company has been appointed, and now the CFO (who has been leading almost all of the investor presentations) has stepped down.

Change is most clearly taking place at this company and I think the clear intention is to finally begin generating shareholder value, or at least try.

Quite odd and unexpected. The strength of the successor, when announced, will undoubtedly tell us about the direction we can expect the company to be going in the future. Here's hoping this is part of some grand masterplan laying out the foundations for the roll out to commercialisation.

I wish MH the best for the future either way, he may have had his detractors (which CFO doesn't?, but he is a decent bloke and a good servant to the company.

Skip to around 1h37m onwards for the good stuff.

https://youtu.be/eyPksoILpxo

What a company, highly excited across all timescales for the potential on offer here.

It also says last updated 8th October 2020

Frustrating to see the share price drop back over the past few weeks again, however I think it's worth viewing this in the context of the wider sector. Biotechs had a good run last year, but since the turn of the year (and especially so in the last month) there are very few that are actually up - Rene being one of the exceptions, up around 20% since 31st Dec.

Once the tailwinds return to the sector, there will be plenty to look forward to. Picked up some more at 98p this morning and more than comfortable with my holding.

Acuere - you're quite right, thanks for the response.

Maxcyte are close to the automatic entry value threshold for FTSE250, by looks of it:

http://www.stockchallenge.co.uk/ftse.php

Anyone aware of any commentary on this point? Would be good to get established in this index prior to NASDAQ listing. FTSE100 obviously being the long term aim here as well.

Decent mention for Heiq on this vox market share chat. Skip to around 31m if you don't want to watch the full thing.

https://youtu.be/HoTULGVSEvM

Amarti Global certainly seem bullish about the prospects for this company.

Surprised - I somewhat suspect that post may have been aimed at myself, which is fair enough. I haven't been invested here as long as a number of posters, so perhaps my optimism and resilience needs additional time to complete its metamorphosis into anguish and despair. Time will indeed tell, but I remain confident that the market is not correctly valuing the scope (and likelihood) of the opportunity that exists here.

ASRS conference is October 8 to 12th in Texas. I don't believe the presenters have been announced. Think the location and date got change, probably because of covid (like everything), but don't know.

https://www.asrs.org/annual-meeting

AAO is November in New Orleans. Again, don't think presenters have been announced. Both are still open for abstract submissions.

https://www.aao.org/annual-meeting/program-highlights/program-highlights-2

Not sure about the Oxford site, but you would imagine if that hasn't progressed then it will be very soon, with how the restrictions are being eased in this country. They may therefore be able to present 6 months of data at those conferences, all going well.

Also appointed Walbrook to be new investor relations and PR manager. Can only be a good thing, as the company has struggled in this area for a while.

https://twitter.com/WalbrookPR/status/1364861173708058627?s=19

https://twitter.com/WalbrookPR/status/1364862083377020929?s=19

New joint broker and 3 presentations within 2 weeks. Not sure what to make of it, but it does sound like there is a significant publicity drive, that's for sure.

Nasdaq listing being lined up? Or is that me getting ahead of myself?

New article providing a good general overview on the exosome market:

https://www.labiotech.eu/in-depth/exosome-therapy/

If only there was some sort of solution to this....

https://www.bbc.com/news/uk-england-leicestershire-56171006